4D Molecular Therapeutics, Inc. Marketable Securities (Current)
4D Molecular Therapeutics, Inc. (FDMT) had Marketable Securities (Current) of $290.96 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-13
- 2026-06-30: Marketable Securities, Current $290.96M.
- 2026-03-31: Marketable Securities, Current $318.40M.
- 2025-12-31: Marketable Securities, Current $342.41M.
- 2025-09-30: Marketable Securities, Current $256.51M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $290.96M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $318.40M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $342.41M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $256.51M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $216.07M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $187.91M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $275.54M 10-K · filed 2026-03-18 |
| 2024-09-30 | $314.35M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $352.88M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $250.32M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $39.12M 10-K · filed 2025-02-28 |
| 2023-09-30 | $43.99M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $74.03M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $121.89M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $161.20M 10-K · filed 2024-02-29 |
| 2022-09-30 | $119.42M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $127.60M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $160.18M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $94.78M 10-K · filed 2023-03-15 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |